Combination therapy of parp inhibitors

A kit containing one or more pharmaceutical preparations of a PARP inhibitor and one or more pharmaceutical preparations of a DNA damaging anti-cancer drug, wherein the pharmaceutical preparations of the PARP inhibitor and the pharmaceutical preparations of the DNA damaging anti-cancer drug are individually packaged, wherein in the pharmaceutical preparation of PARP inhibitor, the content of the PARP inhibitor is able to provide an effective daily dose of the PARP inhibitor when being administered alone, and in the pharmaceutical preparation of the DNA damaging anti-cancer drug, the content of the DNA damaging anti-cancer drug is able to provide a daily dose that is about 1/12th to about ⅕th of the daily dose of the DNA damaging anti-cancer drug when used alone or in combination with other drugs or therapies;

• wherein the PARP inhibitor is selected from the group consisting of compounds represented by Formula I:
• or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein:
• Ar is an optionally substituted aryl or an optionally substituted heteroaryl;
• and
• R1-R6 are independently hydrogen, halo, optionally substituted amino, optionally substituted alkoxy, optionally substituted C1-10 alkyl, alkenyl, alkynyl, nitro, cyano, acylamido, hydroxy, thiol, acyloxy, azido, carboxy, ethylenedioxo, hydroxylamido or optionally substituted alkylthiol;
• wherein the DNA damaging anti-cancer drug is an alkylating agent anti-cancer drug selected from the group consisting of nitrogen mustard N-oxide, cyclophosphamide, ifosfamide, thiotepa, ranimustine, nimustine, Temozolomide (TMZ), altretamine, apaziquone, brostallicin, bendamustine, carmustine, estramustine, fotemustine, glufosfamide, mafosfamide, bendamustine, dibromidulcitol, cisplatin, carboplatin, eptaplatin, lobaplatin, nedaplatin, oxaliplatin and satraplatin.